Measuring Biomarkers at Every Stage of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

request more information

Click through the alphabet to see available assays

Simoa® In Action:

Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations.

Olsen et al. Simoa assays were developed to measure AKT, ERK, and cyclin d concentrations in colon cancer patients. Researchers demonstrated an association between levels of these signaling proteins and mutational BRAF status.

Simoa® In Action:

Enrichment of circulating tumor-derived extracellular vesicles from human plasma

Yoh et al. Researchers developed and validated an enrichment method for tumor-derived extracellular vesicles (EVs) in the blood of lung and breast cancer patients using Simoa, providing new insights into enrichment of specific EV subtypes for liquid biopsy.